PRETTY GIRL

BEIJING, Oct. 29 -- China's Ministry of Health said Wednesday that 2,390 infants nationwide were still receiving hospital treatment for kidney diseases caused by tainted powdered milk.

One was in a serious condition, the ministry said.

The number of baby patients in hospital dropped by one-third from a week ago when more than 3,600 infants were still hospitalized.

It said 48,514 children had recovered and left hospital since milk powder produced by Sanlu Group was found to contain the banned chemical melamine in mid September.

On Wednesday alone, 90 children were newly hospitalized and 218had recovered, the ministry said.

More than 4,500 medical institutions nationwide had conducted free treatment and examination of children feared to have been poisoned in the scandal.

BEIJING, Oct. 29 -- China's Ministry of Health said Wednesday that 2,390 infants nationwide were still receiving hospital treatment for kidney diseases caused by tainted powdered milk.

One was in a serious condition, the ministry said.

The number of baby patients in hospital dropped by one-third from a week ago when more than 3,600 infants were still hospitalized.

It said 48,514 children had recovered and left hospital since milk powder produced by Sanlu Group was found to contain the banned chemical melamine in mid September.

On Wednesday alone, 90 children were newly hospitalized and 218had recovered, the ministry said.

More than 4,500 medical institutions nationwide had conducted free treatment and examination of children feared to have been poisoned in the scandal.

WASHINGTON, Oct. 31 -- The U.S. Food and Drug Administration has approved a new drug, Toviaz (fesoterodine fumarate), to help patients suffering from overactive bladder (OAB), according to a statement by the agency on Friday.

The drug works by relaxing the smooth muscle tissue of the bladder, thus reducing the urinary frequency, urge to urinate, and sudden urinary incontinence, that are characteristic symptoms of OAB.

"Patients who suffer from overactive bladder face quality of life issues that can hamper their ability to enjoy life to its fullest," said George Benson, deputy director, Division of Reproductive and Urologic Products at the FDA's Center for Drug Evaluation and Research. "This new drug will provide an additional treatment option to help them manage problems with an overactive bladder."

Toviaz is manufactured by Schwarz Pharma of Zwickau, Germany and is distributed by Pfizer Inc. of New York, N.Y.. The drug will be available by prescription only, as an extended release tablet in either 4 mg or 8 mg dosage strengths. It is to be administered once daily. The recommended starting dose is 4 mg, which can be increased to 8 mg if needed, based upon individual response and tolerability. Toviaz is only approved for adults.

　

WASHINGTON, Oct. 31 -- The U.S. Food and Drug Administration has approved a new drug, Toviaz (fesoterodine fumarate), to help patients suffering from overactive bladder (OAB), according to a statement by the agency on Friday.

The drug works by relaxing the smooth muscle tissue of the bladder, thus reducing the urinary frequency, urge to urinate, and sudden urinary incontinence, that are characteristic symptoms of OAB.

"Patients who suffer from overactive bladder face quality of life issues that can hamper their ability to enjoy life to its fullest," said George Benson, deputy director, Division of Reproductive and Urologic Products at the FDA's Center for Drug Evaluation and Research. "This new drug will provide an additional treatment option to help them manage problems with an overactive bladder."

Toviaz is manufactured by Schwarz Pharma of Zwickau, Germany and is distributed by Pfizer Inc. of New York, N.Y.. The drug will be available by prescription only, as an extended release tablet in either 4 mg or 8 mg dosage strengths. It is to be administered once daily. The recommended starting dose is 4 mg, which can be increased to 8 mg if needed, based upon individual response and tolerability. Toviaz is only approved for adults.

　

WASHINGTON, Oct. 31 - According to new research by U.S. scientists, the degree of change in blood triglyceride levels following a fatty meal may indicate susceptibility to diet-induced obesity.

The findings, published in the International Journal of Obesity and available here on Friday, open doors to new methods of identifying people, including children, who are at risk for becoming obese.

Triglycerides are a form of fat that is transported in the blood and stored in the body's fat tissues. They are found in foods and also are manufactured by the body.

"These findings suggest we may someday be able to use a simple blood test to identify those at risk for obesity," said senior author Mark Friedman, the researcher at Monell Center. "The ability to identify more susceptible individuals would make it possible to target obesity-prevention resources on those who need them most.

The global obesity epidemic is thought to be caused in part by consumption of a diet high in fat and carbohydrates, which promotes weight gain. This propensity to gain weight and become obese when consuming a high-fat diet is at least partially controlled by genes, with some individuals gaining more than others while eating the same diet.

The researchers screened rats for vulnerability to diet-induced obesity by measuring the increase in blood triglyceride levels following a single high-fat meal. They then fed the rats a diet high in fat over the next four weeks.

They were able to predict which animals would become obese over the four-week period by examining the earlier metabolic response to the high-fat meal: the smaller the triglyceride change, the greater the weight gain.

There currently are no simple biomarkers for predicting susceptibility to diet-induced obesity, and thus no clinical tests that assist physicians in identifying those at risk for becoming obese. The current findings suggest that a change in blood triglyceride levels may someday be used as such a tool.

Future studies will entail a thorough investigation of the mechanism behind differences in the change in blood triglycerides.

WASHINGTON, Oct. 31 - According to new research by U.S. scientists, the degree of change in blood triglyceride levels following a fatty meal may indicate susceptibility to diet-induced obesity.

The findings, published in the International Journal of Obesity and available here on Friday, open doors to new methods of identifying people, including children, who are at risk for becoming obese.

Triglycerides are a form of fat that is transported in the blood and stored in the body's fat tissues. They are found in foods and also are manufactured by the body.

"These findings suggest we may someday be able to use a simple blood test to identify those at risk for obesity," said senior author Mark Friedman, the researcher at Monell Center. "The ability to identify more susceptible individuals would make it possible to target obesity-prevention resources on those who need them most.

The global obesity epidemic is thought to be caused in part by consumption of a diet high in fat and carbohydrates, which promotes weight gain. This propensity to gain weight and become obese when consuming a high-fat diet is at least partially controlled by genes, with some individuals gaining more than others while eating the same diet.

The researchers screened rats for vulnerability to diet-induced obesity by measuring the increase in blood triglyceride levels following a single high-fat meal. They then fed the rats a diet high in fat over the next four weeks.

They were able to predict which animals would become obese over the four-week period by examining the earlier metabolic response to the high-fat meal: the smaller the triglyceride change, the greater the weight gain.

There currently are no simple biomarkers for predicting susceptibility to diet-induced obesity, and thus no clinical tests that assist physicians in identifying those at risk for becoming obese. The current findings suggest that a change in blood triglyceride levels may someday be used as such a tool.

Future studies will entail a thorough investigation of the mechanism behind differences in the change in blood triglycerides.

Son DamBi (Koren Sexy Star) Powerful Dance

Son Dambi was Born on September 25, 1983. She debuted as a singer in 2007.

Dambi has previously appeared in music videos for Paran and MYV and various big name commercials, shooting to stardom with an mp3 player CF in which she unleashed her dance moves opposite Poppin' Hyun Joon.

Her debut single, Cry Eye, was produced and composed by Jang Joon Ho and The lyrics were provided by Brian Kim. While the single gathered much attention, it was not a big hit as expectd.

After training in the United States after Cry Eye, Son Dam Bi returned to Korea and released a mini album, Son Dambi Mini Album Vol.1, with a focus on electronica (departing from her previous style of crunk pop) on April 29, 2008. The lead title was Bad Boy, produced by Brave Brothers. Dam Bi was the first artist outside of YG Entertainment that had his/her album produced by this team.
Label : son dambi , korean sexy , sexy girls , korean girls , Sexy Star , sexy girls